CYP2D6 and breast cancer: Long‐term use (cDDD ≥ 365) was significantly associated with reduced breast cancer risk:○OR: 0.77, 95% CI: 0.61–0.97, p = 0.029Moderate use (cDDD 30–179) also showed a protective effect:○OR: 0.68, 95% CI: 0.55–0.82, p < 0.001No increased risk was observed at any dosage level of sertralineSertraline may exert anti‐inflammatory effects, contributing to reduced carcinogenic riskCompared to SSRIs like paroxetine or fluoxetine, sertraline is a weaker CYP2D6 inhibitor, posing less interference with tamoxifen metabolism, which is relevant in breast cancer treatment